Dupilumab efficacy and safety in patients with asthma and blood eosinophils ≥500 cells·µL(-1)

Dupilumab is well tolerated and improves clinical outcomes in patients with asthma and high eosinophils (≥500 cells·µL(−1)). Improvements in clinical outcomes correlate with eosinophil counts, demonstrating dupilumab efficacy in those with high eosinophils. https://bit.ly/3Jxvicb